NasdaqGS - Delayed Quote USD

Novavax, Inc. (NVAX)

4.1500 -0.0400 (-0.95%)
At close: April 24 at 4:00 PM EDT
4.1000 -0.05 (-1.20%)
Pre-Market: 9:15 AM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. John Joseph Trizzino B.S., M.B.A. President & COO 641.22k -- 1960
Mr. James Patrick Kelly C.F.A. Executive VP, CFO & Treasurer 644.32k -- 1966
Mr. Stanley Charles Erck Advisor 1.09M -- 1948
Mr. John Charles Jacobs M.B.A. CEO & Director -- -- 1967
Mr. Richard P. Crowley Executive VP & COO -- -- 1957
Mr. Troy Morgan Esq., J.D. Senior VP & Chief Compliance Officer -- -- 1971
Mr. Mark Casey Executive VP, Chief Legal Officer & Corporate Secretary -- -- --
Ms. Erika S. Trahan Associate Director of Investor & Public Relations -- -- --
Mr. Ian J. Watkins Executive VP & Chief Human Resources Officer -- -- 1963
Ms. Silvia Taylor M.B.A. Executive VP and Chief Corporate Affairs & Advocacy Officer -- -- --

Novavax, Inc.

700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000 https://www.novavax.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1,543

Description

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 5; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Novavax, Inc. Earnings Call

Related Tickers

MRNA Moderna, Inc.
108.85
+0.89%
 
IOVA Iovance Biotherapeutics, Inc.
11.71
-1.26%
 
INO Inovio Pharmaceuticals, Inc.
10.16
-2.03%
 
VXRT Vaxart, Inc.
0.7097
-4.79%
 
BNTX BioNTech SE
88.09
-0.45%
 
OCGN Ocugen, Inc.
1.1800
-5.60%
 
IBRX ImmunityBio, Inc.
4.8200
-12.20%
 
BLUE bluebird bio, Inc.
0.9229
-4.91%
 
SAVA Cassava Sciences, Inc.
20.74
+0.92%
 
VKTX Viking Therapeutics, Inc.
65.07
+0.22%